Abstract
Glioblastoma (GBM) is the most aggressive astrocytoma. Despite maximum treatment, the GBM usually recurs and the patient survival is poor. Thus, understanding the molecular mechanism of GBM progression will be meaningful to ameliorate this situation. In this study, collapsin response mediator protein 2 (CRMP2) and Ubc9 protein levels were evaluated in three GBM cell lines. Sumoylated CRMP2 were enriched and immunoprecipitated using SUMO1 and IgG antibodies. CRMP2-K374A mutant was generated by site-direct mutagenesis. All indicated constructs were transfected into GL15 cells, and the corresponding proliferation-promoting effect was assessed through cell proliferation ratio. The t-CSM peptide was used to disturb Ubc9-CRMP2 interaction. CRMP2 is expressed in all tested GBM cell lines. The Ubc9 protein levels are positively correlated with CRMP2 level, and both can promote GBM cell proliferation. Blocking CRMP2 SUMOylation through SUMOylation-incompetent mutant or small peptide suppresses CRMP2-induced GBM cell proliferation. This study demonstrates that the CRMP2 SUMOylation exists widely in GBM cells and drives glioblastoma proliferation. CRMP2 SUMOylation inhibition can significantly suppress GBM proliferation in vitro.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arimura N, Inagaki N, Chihara K, Ménager C, Nakamura N, Amano M, Iwamatsu A, Goshima Y, Kaibuchi K (2000) Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 275:23973–23980. https://doi.org/10.1074/jbc.M001032200
Arimura N, Menager C, Fukata Y, Kaibuchi K (2004) Role of CRMP-2 in neuronal polarity. J Neurobiol 58:34–47. https://doi.org/10.1002/neu.10269
Arimura N, Menager C, Kawano Y, Yoshimura T, Kawabata S, Hattori A, Fukata Y, Amano M, Goshima Y, Inagaki M, Morone N, Usukura J, Kaibuchi K (2005) Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol 25:9973–9984. https://doi.org/10.1128/MCB.25.22.9973-9984.2005
Bleeker FE, Molenaar RJ, Leenstra S (2012) Recent advances in the molecular understanding of glioblastoma. J Neuro-Oncol 108:11–27. https://doi.org/10.1007/s11060-011-0793-0
Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R (2009) An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 284:31375–31390. https://doi.org/10.1074/jbc.M109.009951
Chae YC, Lee S, Heo K, Ha SH, Jung Y, Kim JH, Ihara Y, Suh PG, Ryu SH (2009) Collapsin response mediator protein-2 regulates neurite formation by modulating tubulin GTPase activity. Cell Signal 21:1818–1826. https://doi.org/10.1016/j.cellsig.2009.07.017
Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J (2003) Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 28:51–64. https://doi.org/10.1385/MN:28:1:51
Chew LA, Khanna R (2018) CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain. Neuronal Signal 2. https://doi.org/10.1042/NS20170220
Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD, Khanna R (2009) Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci 122:4351–4362. https://doi.org/10.1242/jcs.053280
Dustrude ET, Wilson SM, Ju W, Xiao Y, Khanna R (2013) CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem 288:24316–24331. https://doi.org/10.1074/jbc.M113.474924
Dustrude ET, Moutal A, Yang X, Wang Y, Khanna M, Khanna R (2016) Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. Proc Natl Acad Sci U S A 113:E8443–E8452. https://doi.org/10.1073/pnas.1610531113
Dustrude ET, Perez-Miller S, Francois-Moutal L, Moutal A, Khanna M, Khanna R (2017) A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin) 11:316–328. https://doi.org/10.1080/19336950.2017.1299838
Francois-Moutal L et al (2018) Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain 159:2115–2127. https://doi.org/10.1097/j.pain.0000000000001294
Fukata Y, Itoh TJ, Kimura T, Ménager C, Nishimura T, Shiromizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K (2002) CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol 4:583–591. https://doi.org/10.1038/ncb825
Gallego O (2015) Nonsurgical treatment of recurrent glioblastoma. Curr Oncol 22:e273–e281. https://doi.org/10.3747/co.22.2436
Guo L, Zhang P, Chen Z, Xia H, Li S, Zhang Y, Kobberup S, Zou W, Lin JD (2017) Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J Clin Invest 127:4449–4461. https://doi.org/10.1172/JCI96324
Hay RT (2005) SUMO: a history of modification. Mol Cell 18:1–12. https://doi.org/10.1016/j.molcel.2005.03.012
Hensley K, Kursula P (2016) Collapsin response mediator protein-2 (CRMP2) is a plausible etiological factor and potential therapeutic target in Alzheimer’s disease: comparison and contrast with microtubule-associated protein tau. J Alzheimers Dis 53:1–14. https://doi.org/10.3233/JAD-160076
Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 43:180–191. https://doi.org/10.1007/s12035-011-8166-4
Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, Takenawa T, Kaibuchi K (2005) CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol 25:9920–9935. https://doi.org/10.1128/MCB.25.22.9920-9935.2005
Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4:54. https://doi.org/10.3978/j.issn.2305-5839.2016.01.25
Liu BP, Strittmatter SM (2001) Semaphorin-mediated axonal guidance via Rho-related G proteins. Curr Opin Cell Biol 13:619–626
McNeill KA (2016) Epidemiology of brain tumors. Neurol Clin 34:981–998. https://doi.org/10.1016/j.ncl.2016.06.014
Moutal A, Villa LS, Yeon SK, Householder KT, Park KD, Sirianni RW, Khanna R (2018) CRMP2 phosphorylation drives glioblastoma. Cell Proliferation Mol Neurobiol 55:4403–4416. https://doi.org/10.1007/s12035-017-0653-9
Soutar MP, Thornhill P, Cole AR, Sutherland C (2009) Increased CRMP2 phosphorylation is observed in Alzheimer’s disease; does this tell us anything about disease development? Curr Alzheimer Res 6:269–278
Tatham MH, Kim S, Yu B, Jaffray E, Song J, Zheng J, Rodriguez MS, Hay RT, Chen Y (2003) Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation. Biochemistry 42:9959–9969. https://doi.org/10.1021/bi0345283
Yamashita N, Goshima Y (2012) Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status. Mol Neurobiol 45:234–246. https://doi.org/10.1007/s12035-012-8242-4
Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120:137–149. https://doi.org/10.1016/j.cell.2004.11.012
Yoshimura T, Arimura N, Kaibuchi K (2006) Molecular mechanisms of axon specification and neuronal disorders. Ann N Y Acad Sci 1086:116–125. https://doi.org/10.1196/annals.1377.013
Young RM, Jamshidi A, Davis G, Sherman JH (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 3:121. https://doi.org/10.3978/j.issn.2305-5839.2015.05.10
Zhang JN, Koch JC (2017) Collapsin response mediator protein-2 plays a major protective role in acute axonal degeneration. Neural Regen Res 12:692–695. https://doi.org/10.4103/1673-5374.206631
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA (2018) Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9:476. https://doi.org/10.1038/s41467-017-02811-7
Funding
This study was funded by Science & Technology Project of Cangzhou (No. 162302141).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, L., Ji, S. Inhibition of Ubc9-Induced CRMP2 SUMOylation Disrupts Glioblastoma Cell Proliferation. J Mol Neurosci 69, 391–398 (2019). https://doi.org/10.1007/s12031-019-01368-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-019-01368-y